Lantern Pharma Inc (LTRN) Opciones

LTRN under $5

Finally an UP day. 'hope institutions will see this nugget soon

https://www.zacks.com/stock/news/2300964/the-zacks-analyst-blog-highlights-danaher-morgan-stanley-pfizer-elite-pharmaceuticals-and-oil-dri
https://www.zacks.com/stock/news/2300922/zacks-initiates-coverage-of-elite-pharmaceuticals-with-outperform-recommendation

Nice drop

LTRN under $10

Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc

Monk, take a look at ANV*S. Data is due sometime in April, Parkinsons and Alzheimers. They just did a private placement on Friday and another one today to an institutional investor. "Subject to Certain Conditions". Looks like April is go time.

I think we can revisit the high again hopefully this week. Been here since 7.20

10-K filing, Earnings Webcast, Presentation in link below from LTRN company website


https://ir.lanternpharma.com/news-events/press-releases/detail/150/lantern-pharma-reports-fourth-quarter-fiscal-year-2023

LTRN new 52 hi

Another very good day today.

LTRN 10Q due 3/18

Very good move on Friday.

This company will see 3 digit dollars, how soon? All depends on just one science behind their Artificial Intelligence to decode one cancer indication the rest will be history.

This is going to have one heck of a run.

Will they break 10.00!??

AI is the next .com and AI's application in medicine and pharma will be a game changer.

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors. The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284, a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma. In addition, it offers LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.